Inactivation of three emerging viruses – severe acute respiratory syndrome coronavirus, Crimean–Congo haemorrhagic fever virus and Nipah virus – in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light

Vox Sanguinis

Volumn 115, Issue 3, 2020, Pages 146-151

  Eickmann, Markus ^a   Gravemann, Ute ^b   Handke, Wiebke ^b   Tolksdorf, Frank ^c   Reichenberg, Stefan ^c   Müller, Thomas H ^b   Seltsam, Axel ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Institute Springe   (Germany)

^c MacoPharma International GmbH   (Germany)

Author keywords

methylene blue; pathogen inactivation; plasma; platelet concentrates; ultraviolet light

Indexed keywords

METHYLENE BLUE; THROMBOCYTE CONCENTRATE;

ARTICLE; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; ID50 (MEDIAN INFECTIOUS DOSE); ILLUMINATION; LIMIT OF DETECTION; NIPAH VIRUS; NIPAH VIRUS INFECTION; NONHUMAN; PLASMA TRANSFUSION; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; THROMBOCYTE TRANSFUSION; TISSUE CULTURE; ULTRAVIOLET C RADIATION; VIRUS INACTIVATION; VIRUS LOAD; BLOOD TRANSFUSION; DRUG EFFECT; HUMAN; LIGHT; PLASMA; RADIATION RESPONSE; THROMBOCYTE; ULTRAVIOLET RADIATION; VIROLOGY;

BLOOD PLATELETS; BLOOD TRANSFUSION; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HUMANS; LIGHT; METHYLENE BLUE; NIPAH VIRUS; PLASMA; SARS VIRUS; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

EID: 85077906975     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12888     Document Type: Article

References (34)

1. Stramer SL, Hollinger FB, Katz LM, et al.: Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49:1S–29S
2. Stramer SL: Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser 2014; 9:30–6
3. Bahar B, Schulz WL, Gokhale A, et al.: Blood utilisation and transfusion reactions in adult patients transfused with conventional or pathogen-reduced platelets. Br J Haematol 2019. https://doi.org/10.1111/bjh.16187 [Epub ahead of print].
4. Seltsam A, Muller TH: Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013; 162:442–54
5. Mohr H, Steil L, Gravemann U, et al.: A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009; 49:2612–24
6. Seltsam A, Muller TH: UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011; 38:43–54
7. Kim S, Handke W, Gravemann U, et al.: Mitochondrial DNA multiplex real-time polymerase chain reaction inhibition assay for quality control of pathogen inactivation by ultraviolet C light in platelet concentrates. Transfusion 2018; 58:758–65
8. Mohr H, Lambrecht B, Selz A: Photodynamic virus inactivation of blood components. Immunol Invest 1995; 24:73–85
9. Seghatchian J, Walker WH, Reichenberg S: Updates on pathogen inactivation of plasma using Theraflex methylene blue system. Transfus Apher Sci 2008; 38:271–80
10. Politis C, Kavallierou L, Hantziara S, et al.: Haemovigilance data on the use of methylene blue virally inactivated fresh frozen plasma with the Theraflex MB-Plasma System in comparison to quarantine plasma: 11 years' experience. Transfus Med 2014; 24:316–20
11. Williamson LM, Cardigan R, Prowse CV: Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003; 43:1322–9
12. Faddy HM, Fryk JJ, Prow NA, et al.: Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light. Transfusion 2016; 56:1548–55
13. Fryk JJ, Marks DC, Hobson-Peters J, et al.: Reduction of Zika virus infectivity in platelet concentrates after treatment with ultraviolet C light and in plasma after treatment with methylene blue and visible light. Transfusion 2017; 57:2677–82
14. Eickmann M, Gravemann U, Handke W, et al.: Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively. Transfusion 2018; 58:2202–7
15. Arnason NA, Johannson F, Landro R, et al.: Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions. Transfusion 2019; 59:3727–3735
16. Castro E, Girones N, Guerrero N, et al.: The effectiveness of UVC pathogen inactivation system on reducing the Trypansosoma cruzi and Leishmania infantum burden in platelets. Vox Sang 2008; 95:290
17. Castro E, Gonzalez LM, Rubio JM, et al.: The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets. Transfusion 2014; 54:2207–16
18. Gravemann U, Handke W, Lambrecht B, et al.: Ultraviolet C light efficiently inactivates nonenveloped hepatitis A virus and feline calicivirus in platelet concentrates. Transfusion 2018; 58:2669–74
19. Gravemann U, Handke W, Muller TH, et al.: Bacterial inactivation of platelet concentrates with the THERAFLEX UV-Platelets pathogen inactivation system. Transfusion 2019; 59:1324–32
20. Seghatchian J, Struff WG, Reichenberg S: Main properties of the THERAFLEX MB-plasma system for pathogen reduction. Transf Med Hemother 2011; 38:55–64
21. Spearman C: The method of "right and wrong cases" ("constant stimuli") without Gauss's formulae. Br J Psychol 1908; 2:277–82
22. Kaerber G: Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1931; 162:480–3
23. Agafonov AP, Gus'kov AA, Ternovoi VA, et al.: Primary characterization of SARS coronavirus strain Frankfurt 1. Dokl Biol Sci 2004; 394:58–60
24. Olschlager S, Gabriel M, Schmidt-Chanasit J, et al.: Complete sequence and phylogenetic characterisation of Crimean-Congo hemorrhagic fever virus from Afghanistan. J Clin Virol 2011; 50:90–2
25. Wild TF: Henipaviruses: a new family of emerging Paramyxoviruses. Pathol Biol (Paris) 2009; 57:188–96
26. Woolhouse ME, Haydon DT, Antia R: Emerging pathogens: the epidemiology and evolution of species jumps. Trends Ecol Evol 2005; 20:238–44
27. de Wit E, van Doremalen N, Falzarano D, et al.: SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016; 14:523–34
28. Dunstan RA, Seed CR, Keller AJ: Emerging viral threats to the Australian blood supply. Aust N Z J Public Health 2008; 32:354–60
29. Bente DA, Forrester NL, Watts DM, et al.: Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res 2013; 100:159–89
30. Conger NG, Paolino KM, Osborn EC, et al.: Health care response to CCHF in US soldier and nosocomial transmission to health care providers, Germany, 2009. Emerg Infect Dis 2015; 21:23–31
31. Sharma V, Kaushik S, Kumar R, et al.: Emerging trends of Nipah virus: A review. Rev Med Virol 2019; 29:e2010
32. Ang BSP, Lim TCC, Wang L: Nipah virus infection. J Clin Microbiol 201856(6):e01875-17
33. Nikolay B, Salje H, Hossain MJ, et al.: Transmission of nipah virus - 14 years of investigations in Bangladesh. N Engl J Med 2019; 380:1804–14
34. McCullough J, Alter HJ, Ness PM: Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy. Transfusion 2019; 59:1132–46